A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

Relapsed or Refractory Lymphomas Clinical Trial

Official title: Phase 1 (Dose Escalation)/Phase 2 (Expansion Cohort) Trial of TY101 as a Single Agent in Patients With Locally Advanced/Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

Status Recruiting

Clinical Trial Summary

A multicenter, open-label, dose-escalation and dose-expansion phase 1/2 study, to evaluate TY101 safety, tolerability, pharmacokinetic characteristics, effectiveness and immunogenicity in patients with Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas. The study includes two parts: dose escalation and expansion cohort to evaluate the tolerability and efficacy.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Locally Advanced /Metastatic Solid Tumors
• Lymphoma
• Relapsed or Refractory Lymphomas

• NCT number: NCT04458389
• Study type: Interventional
• Source: Tayu Huaxia Biotech Medical Group Co., Ltd.
• Contact: Guanwen Zeng, PhD
• Phone: 8610-85187670
• Email: kevintseng@tayubiotech.com
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: December 7, 2020
• Completion date: July 31, 2025